BRY812

BRY812 is a novel antibody-drug conjugate (ADC) developed by BioRay Pharmaceutical that targets the human LIV-1 protein (also known as SLC39A6 or ZIP6), a zinc transporter implicated in tumor metastasis and epithelial-mesenchymal transition. The drug uses BioRay’s proprietary CysLink irreversible chemical conjugation technology to attach a cytotoxic payload to an anti-LIV-1 antibody. Upon binding to LIV-1 on the surface of tumor cells, the ADC is internalized via endocytosis and trafficked to lysosomes, where it releases monomethyl auristatin E (MMAE), a microtubule inhibitor. MMAE disrupts tubulin polymerization, causing G2/M cell cycle arrest and apoptosis in LIV-1-expressing tumor cells. Preclinical studies have shown significant antitumor activity with improved safety and stability compared to other ADCs targeting similar pathways. In addition to direct cytotoxicity, BRY812 may induce immunogenic cell death and enhance responses to immunotherapies such as anti-PD-(L)1 agents. It is currently being evaluated for advanced malignancies in Phase I clinical trials[1][2][3][4][5][7].

Other names

anti-LIV-1 antibody-drug conjugate BRY812anti-LIV1 antibody-drug conjugate BRY812anti-LIV 1 antibody-drug conjugate BRY812